Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized, Multicenter, Double-blind, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

NCT07516561 is registered in ClinicalTrials.gov with Apsen Farmaceutica S.A. as lead sponsor.

NCT NCT07516561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07516561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized, Multicenter, Double-blind, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
Lead sponsor
Apsen Farmaceutica S.A.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 7, 2026
Completion date
August 2, 2029
Enrollment
336 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia, androgenetic